MedTrace Logo

Zyprexa and Task Engagement in Schizophrenia

NCT00440843 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2013-12-23

No results posted yet for this study

Summary

Individuals with schizophrenia frequently have impairments in attention. These impairments have been shown to be related to overall functioning. Some research suggests that Olanzapine may be associated with improvement in various aspects of attention. The primary purpose of this study is to determine whether switching from a typical antipsychotic to Olanzapine improves task engagement. Individuals who taking typical antipsychotics will be randomly assigned to either 1) remain on their typical antipsychotic medications, or 2) be switched from their typical antipsychotic medications to Olanzapine. All participants will be enrolled in a twice-weekly 20 session cognitive training program that is specifically designed to target attention deficits and promote active engagement. Improvements in attention will be compared between individuals who remained on their typical antipsychotic medications and those that were switched to Olanzapine.

Conditions

Interventions

DRUG

Olanzapine (Zyprexa)

OLZ

DRUG

Typicals

Stay on typicals regimen

Sponsors & Collaborators

  • Clinical Trials Network of Columbia U, Cornell U, and NY Presbyterian Hospital

    collaborator NETWORK

  • Eli Lilly and Company

    collaborator INDUSTRY

  • VA Connecticut Healthcare System

    lead FED

Principal Investigators

  • Jimmy Choi, Psy.D. · Columbia University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-02-28
Primary Completion
2012-06-30
Completion
2012-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00440843 on ClinicalTrials.gov